Source:http://linkedlifedata.com/resource/pubmed/id/15170169
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2004-7-19
|
| pubmed:abstractText |
A total of 174 newly diagnosed adult acute myeloid leukaemia (AML) patients were treated in first complete remission (CR1) using modified TAM or a combination of triple-alkylating agents followed by autologous transplantation (AT). Cytogenetic risk groups were classified and most patients received mobilized peripheral blood stem/progenitor cells (PBSCs). The infused cell dose consisted of a median of 4.1+/-2 (range, 1.2-17.1)x 10(6)/kg CD34+ cells. With a median follow-up of 51 months (range, 5-131 months) after CR1, the estimated 5-year disease-free survival (DFS) rate was 68 (95% confidence interval (CI), 63-73%) and the event-free survival rate at 5 years was 59 (95% CI, 54-64%). AML patients other than M3 subtype, the long-term DFS rate was 76, 33% for favourable and unfavourable risk groups, respectively. In all, 40 patients had relapses (40/174, 23%) at the median 15 months after CR1 (range, 8-66 months). Overall, seven patients (4%) died in connection with AT. The infused CD34+ cell dose (P=0.0389) was associated with survival by multivariate analysis. In conclusion, two novel conditioning regimens in AT are feasible for adults with variable risk AML followed for over a 10-year period.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0268-3369
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
34
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
215-20
|
| pubmed:meshHeading |
pubmed-meshheading:15170169-Acute Disease,
pubmed-meshheading:15170169-Adolescent,
pubmed-meshheading:15170169-Adult,
pubmed-meshheading:15170169-Alkylating Agents,
pubmed-meshheading:15170169-Disease-Free Survival,
pubmed-meshheading:15170169-Drug Therapy, Combination,
pubmed-meshheading:15170169-Female,
pubmed-meshheading:15170169-Humans,
pubmed-meshheading:15170169-Immunophenotyping,
pubmed-meshheading:15170169-Leukemia, Myeloid,
pubmed-meshheading:15170169-Male,
pubmed-meshheading:15170169-Middle Aged,
pubmed-meshheading:15170169-Stem Cell Transplantation,
pubmed-meshheading:15170169-Time Factors,
pubmed-meshheading:15170169-Transplantation, Autologous,
pubmed-meshheading:15170169-Transplantation Conditioning
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Autologous stem cell transplantation using modified TAM or combination of triple-alkylating agents conditioning regimens as one of the post-remission treatments in patients with adult acute myeloid leukemia in first complete remission.
|
| pubmed:affiliation |
Division of Hematology, Department of Internal Medicine, Catholic Hemopoietic Stem Cell Transplantation Center, The Catholic University of Korea College of Medicine, Seoul, Korea.
|
| pubmed:publicationType |
Journal Article
|